Literature DB >> 12710459

The clinical trials of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock: the tale of two continents.

Edward P Sloan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12710459     DOI： 10.1007/s00134-003-1637-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  12 in total

1.  Post hoc mortality analysis on the efficacy trial of diaspirin cross-linked hemoglobin in the treatment of severe traumatic hemorrhagic shock.

Authors:  C Gillon Ward; Edward P Sloan
Journal:  J Trauma       Date:  2002-11

2.  Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients.

Authors:  G Reah; A R Bodenham; A Mallick; E K Daily; R J Przybelski
Journal:  Crit Care Med       Date:  1997-09       Impact factor: 7.598

3.  Distribution of the probability of survival is a strategic issue for randomized trials in critically ill patients.

Authors:  B Riou; P Landais; B Vivien; P Stell; I Labbene; P Carli
Journal:  Anesthesiology       Date:  2001-07       Impact factor: 7.892

4.  Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution.

Authors:  R J Przybelski; E K Daily; J C Kisicki; C Mattia-Goldberg; M J Bounds; W A Colburn
Journal:  Crit Care Med       Date:  1996-12       Impact factor: 7.598

5.  The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a model of uncontrolled hemorrhage.

Authors:  S C Schultz; C C Powell; D G Burris; H Nguyen; J Jaffin; D S Malcolm
Journal:  J Trauma       Date:  1994-09

6.  A safety assessment of diaspirin cross-linked hemoglobin (DCLHb) in the treatment of hemorrhagic, hypovolemic shock.

Authors:  R J Przybelski; E K Daily; J Micheels; E Sloan; P Mols; L Corne; M D Koenigsberg; W H Bickell; D R Thompson; J D Harviel; S M Cohn
Journal:  Prehosp Disaster Med       Date:  1999 Oct-Dec       Impact factor: 2.040

7.  The informed consent process and the use of the exception to informed consent in the clinical trial of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock. DCLHb Traumatic Hemorrhagic Shock study group.

Authors:  E P Sloan; M Koenigsberg; J Houghton; D Gens; M Cipolle; J Runge; M N Mallory; G Rodman
Journal:  Acad Emerg Med       Date:  1999-12       Impact factor: 3.451

8.  Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group.

Authors:  M L Lamy; E K Daily; J F Brichant; R P Larbuisson; R H Demeyere; E A Vandermeersch; J J Lehot; M R Parsloe; J C Berridge; C J Sinclair; J F Baron; R J Przybelski
Journal:  Anesthesiology       Date:  2000-03       Impact factor: 7.892

9.  DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study.

Authors:  Thoralf Kerner; Olaf Ahlers; Siegfried Veit; Bruno Riou; Michael Saunders; Ulrich Pison
Journal:  Intensive Care Med       Date:  2003-01-23       Impact factor: 17.440

10.  Outcome after hemorrhagic shock in trauma patients.

Authors:  S R Heckbert; N B Vedder; W Hoffman; R K Winn; L D Hudson; G J Jurkovich; M K Copass; J M Harlan; C L Rice; R V Maier
Journal:  J Trauma       Date:  1998-09
View more
  2 in total

Review 1.  Year in review in intensive care medicine: 2003. II. Brain injury, hemodynamics, gastrointestinal tract, renal failure, metabolism, trauma, and postoperative.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2004-06-15       Impact factor: 17.440

2.  A hemoglobin-based multifunctional therapeutic: polynitroxylated pegylated hemoglobin.

Authors:  Carleton Jen Chang Hsia; Li Ma
Journal:  Artif Organs       Date:  2011-09-28       Impact factor: 3.094
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.